Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data

All NewsSeptember 5, 2025

Skye Bioscience’s latest data show nimacimab boosted tirzepatide’s weight loss effects and reduced obesity treatment rebound risk.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent